Cancer
IU Scientists Reengineer Cancer-Protective Regulatory T Cells to Combat Tumors
Indiana University School of Medicine researchers have pioneered an innovative approach to cancer immunotherapy by reprogramming a specific subset of...
How Chemotherapy Interferes with the Body’s Internal Clock
The relentless fight against cancer has long been marked by the harsh reality of treatment-related side effects, many of which...
Groundbreaking Clinical Trial Shows Safety and Molecular Insights of Pre- and Post-Surgery Immunotherapy Combo in Operable Mesothelioma Patients
In a pioneering advancement that could reshape the therapeutic landscape for operable mesothelioma, researchers at the Johns Hopkins Kimmel Cancer...
New Study on High-Grade Serous Carcinomas in Cervical Biopsies Supports Removal of Cervical Serous Carcinoma from WHO Classification
In a groundbreaking clinicopathologic study recently published in the Journal of Clinical and Translational Pathology, researchers have shed critical light...
Cancer Cells Exploit Alternative Pathways to Sustain Their Growth
In the ever-evolving landscape of cancer metabolism, new insights often challenge long-standing paradigms about how malignant cells sustain their aggressive...
Tarlatamab Combined with Anti-PD-L1 Shows Promising Safety and Unprecedented Overall Survival as First-Line Maintenance Therapy Following Chemo-Immunotherapy in ES-SCLC
In a significant advancement within the landscape of lung cancer therapeutics, novel clinical data unveiled at the 2025 International Association...
“‘Rogue’ DNA Circles Uncover Earliest Insights into Deadly Brain Cancer Development”
‘Rogue’ DNA Rings Offer Groundbreaking Insights into Early Development and Aggressiveness of Glioblastoma A pioneering international research effort has uncovered...
Major Data Updates and New Study Broaden the Kids First Data Ecosystem
The Gabriella Miller Kids First Pediatric Research Program (Kids First) at the National Institutes of Health (NIH) has once again...
BMS-986504 Shows Lasting Efficacy in MTAP-Deleted NSCLC, Targeting EGFR and ALK-Positive Tumors
In a groundbreaking development in the fight against non-small cell lung cancer (NSCLC), researchers have unveiled promising results from a...
EA5181 Phase 3 Trial Shows No Overall Survival Advantage for Concurrent Plus Consolidative Durvalumab Over Consolidation Alone in Unresectable Stage 3 NSCLC
(Barcelona, Spain – September 8, 2025, 10:45 a.m. CEST / UTC +2) — In a pivotal development presented at the...
Video-Assisted Thoracoscopy Surgery Lowers Mortality by 21% Compared to Lobectomy
Minimally Invasive Surgery in Early-Stage Lung Cancer Demonstrates Significant Survival Advantage Over Traditional Methods Barcelona, Spain – In a landmark...
Phase III Trial Shows Hypofractionated Radiotherapy Plus Chemotherapy Matches Survival Rates and Reduces Toxicity Compared to Conventional Treatment in Limited-Stage SCLC
(Barcelona, Spain — September 8, 2025) — A pivotal multi-center, randomized phase III clinical trial has recently demonstrated that a...
UK Study Finds Lung Cancer Screening Benefits Adults Up to Age 80 Who Are Surgical Candidates
(Barcelona, Spain, September 8, 2025, 10:45 a.m. CEST / UTC +2) — Recent findings presented at the prestigious International Association...
NADIM ADJUVANT Trial Highlights Advantages of Chemo-Immunotherapy After Surgery in Stage IB–IIIA NSCLC
Interim findings from the NADIM ADJUVANT Phase III clinical trial conducted by the Spanish Lung Cancer Group (GECP) have unveiled...
Do Early-Stage Cancer Surgery Patients Face Risk of Long-Term Opioid Use?
New insights into the complex dynamics of opioid use following curative-intent cancer surgery reveal a concerning trend in long-term opioid...
Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer
First-in-Human Trial Highlights Breakthrough DLL3-Targeted Therapy for Relapsed Small Cell Lung Cancer In a landmark development in the treatment of...
Phase 2 IDeate-Lung01 Trial Shows Ifinatamab Deruxtecan Achieves High Response Rates in Previously Treated Extensive-Stage Small Cell Lung Cancer
In a groundbreaking advancement for small cell lung cancer (SCLC) therapy, recent data unveiled at the International Association for the...
Zidesamtinib Demonstrates Lasting Efficacy in ROS1 TKI-Pretreated NSCLC, Including Cases with CNS Involvement and ROS1 G2032R Mutations
In a groundbreaking advancement for the treatment of ROS1-positive non-small cell lung cancer (NSCLC), a novel investigational agent, zidesamtinib, has...
Crizotinib Does Not Enhance Disease-Free Survival in Resected Early-Stage ALK-Positive NSCLC
In a significant development in the field of thoracic oncology, recent findings from the Phase 3 E4512 clinical trial have...
FLAURA2 Trial Demonstrates Enhanced Overall Survival with Osimertinib and Chemotherapy in EGFR-Mutated Advanced NSCLC
In a groundbreaking advancement within the realm of targeted oncology, the international cancer research community has witnessed compelling evidence supporting...
